- Home
- THQ vs KALV Comparison
THQ vs KALV Comparison
Compare THQ & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THQ
- KALV
- Stock Information
- Founded
- THQ 2014
- KALV N/A
- Country
- THQ United States
- KALV United States
- Employees
- THQ N/A
- KALV N/A
- Industry
- THQ Finance Companies
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- THQ Finance
- KALV Health Care
- Exchange
- THQ Nasdaq
- KALV Nasdaq
- Market Cap
- THQ 763.4M
- KALV 725.3M
- IPO Year
- THQ N/A
- KALV N/A
- Fundamental
- Price
- THQ $17.22
- KALV $14.94
- Analyst Decision
- THQ
- KALV Strong Buy
- Analyst Count
- THQ 0
- KALV 9
- Target Price
- THQ N/A
- KALV $26.29
- AVG Volume (30 Days)
- THQ 158.9K
- KALV 1.8M
- Earning Date
- THQ 01-01-0001
- KALV 07-10-2025
- Dividend Yield
- THQ 7.53%
- KALV N/A
- EPS Growth
- THQ N/A
- KALV N/A
- EPS
- THQ N/A
- KALV N/A
- Revenue
- THQ N/A
- KALV N/A
- Revenue This Year
- THQ N/A
- KALV N/A
- Revenue Next Year
- THQ N/A
- KALV $347.19
- P/E Ratio
- THQ N/A
- KALV N/A
- Revenue Growth
- THQ N/A
- KALV N/A
- 52 Week Low
- THQ $15.29
- KALV $7.30
- 52 Week High
- THQ $20.38
- KALV $16.32
- Technical
- Relative Strength Index (RSI)
- THQ 39.75
- KALV 59.29
- Support Level
- THQ $16.93
- KALV $15.20
- Resistance Level
- THQ $17.67
- KALV $16.09
- Average True Range (ATR)
- THQ 0.31
- KALV 0.84
- MACD
- THQ -0.04
- KALV 0.02
- Stochastic Oscillator
- THQ 25.83
- KALV 61.34
About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.